The substantial outperformance of Novo Nordisk over the past decade, as highlighted by its average annual return of 19.12% and its current market capitalization, indicates a strong and consistent growth trajectory. This historical performance, especially in comparison to the broader market, suggests a positive outlook for NVO's stock in the short term, assuming the company maintains its growth momentum.